Second Sight Medical Products, Inc. (EYES)
(Delayed Data from NSDQ)
$0.99 USD
+0.01 (0.58%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.99 USD
+0.01 (0.58%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Company News for May 13, 2021
by Zacks Equity Research
Companies in the news are: TM, LHDX, EYES, CVI
Second Sight Medical Products (EYES) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Second Sight Medical Products (EYES) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Apr 1, 2020
by Zacks Equity Research
Companies In The News Are: KNSA, EYEG, VBIV, EYES
Second Sight Medical Products (EYES) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 4.08% and -40.12%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Second Sight Medical Products (EYES) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Second Sight Medical Products (EYES) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 0.00% and -49.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Second Sight Medical Products (EYES) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Second Sight Medical Products (EYES) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 0.00% and 183.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Second Sight Medical Products (EYES) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Second Sight Medical Products (EYES) delivered earnings and revenue surprises of -66.67% and -33.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: VALE, Second Sight, Carbonite, Arconic and vTv
by Zacks Equity Research
Zacks.com featured highlights include: VALE, Second Sight, Carbonite, Arconic and vTv
Get Over Bargain Hunting: Tap 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight
by Zacks Equity Research
Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight
Rising P/E an Overlooked Criterion: 5 Top Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratio.
Second Sight Medical Products Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Second Sight Medical Products has been struggling lately, but the selling pressure may be coming to an end soon
Second Sight Medical Products (EYES) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 21.43% and -9.44%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Second Sight Medical Products (EYES) Q3 Earnings Expected to Decline
by Zacks Equity Research
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Second Sight Medical Products (EYES) Q3 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Second Sight Medical Products (EYES): Moving Average Crossover Alert
by Zacks Equity Research
Second Sight Medical Products, Inc. (EYES) could be a stock to avoid from a technical perspective
Second Sight (EYES) Catches Eye: Stock Jumps 12.7%
by Zacks Equity Research
Second Sight (EYES) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.
Second Sight Medical (EYES) in Focus: Stock Moves 12.1% Higher
by Zacks Equity Research
Second Sight Medical (EYES) was a big mover last session, as the company saw its shares more than 12% on the day amid huge volumes.